The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on BPMC stock, giving a Buy rating today. Andrew Fein’s rating ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...

At the recent Eudēmonia Summit, Dr. Sara Gottfried explained why understanding the root cause of chronic illness is more ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.